Visual Universitätsmedizin Mainz

Aktuelles

 

Das Studienzentrum der Hautklinik sucht Patienten mit

 

Chronischer spontaner Nesselsucht

 

–  Melden sie sich  –

 

Das Studienzentrum (CRC - Clinical Research Center) der Hautklinik sucht Studienteilnehmer/ innen ab 18 Jahre, die Interesse an der Durchführung dieser Studie haben. Patienten mit spontan auftretender Nesselsucht oder kälteassoziierter Nesselsucht, welche auf Antihistaminika nicht angesprochen haben.

 

Sollten Sie Interesse an einer Teilnahme haben, nehmen Sie Kontakt mit uns auf. Weitere Informationen teilen wir Ihnen gerne in einem persönlichen Gespräch mit.

 

Wir freuen uns auf Ihren Anruf!

 

Kontakt:
CRC-Studienzentrum/ Hautklinik Geb. 401/1.Stock
Universitätsmedizin Mainz, Langenbeckstr. 1, 55131 MainzTelefon: 06131-17 5732

E-Mail:  crc-hautklinik@unimedizin-mainz.de

Aktuelle Studien

Indikation

Protokollnummer

Titel

Phase

Beschreibung

Psoriasis vulgaris bei Kindern

RD.06.SPR.18131

A multicenter open label uncontrolled study of the long term safety and efficacy of calcitriol 3 mcg/g ointment applied twice daily for 26 weeks in pediatric subjects (2 to 16 years and 11 months of age) with mild to moderate plaque psoriasis

IV

topisches Vitamin D bei Kindern ab 2.tem Lebensjahr bei leichter bis moderater Psoriasis

Chronisch spontane Urtikaria

GS39684

A Phase IIa, multicenter, randomized, double-blind, placebo-controlled pilot study of GDC-0853 in Patients with refractory chronic spontaneous urticaria (CSU)

IIa

Bruton-Tyrosinkinas systemisch oral bei Erwachsenen mit therapieresistenter Urtikaria

Kälteurtikaria

CURES

A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)

II

Rilonacept systemisch subkutan bei Erwachsen mit Kälteurtikaria

Cutaner Lupus Erythematodes

204860

A double-blind (sponsor unblinded) study to investigate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical effect of repeat dosing of GSK2646264 in cutaneous lupus erythematosus patients

I

Topische Therapie bei Erwachsenen zwischen 18-70 Jahren mit mind. 2 aktiven Läsionen in einem Areal

Dermatomyositis

GAM10-08

Prospectiv, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safty of OCTAGAM 10% in patients with Dermatomyositis (ProDERM Study)

III

Octagam 10% über 16 Wochen bei Patienten mit Dermatomyositis

Geschlossen (laufend)

Indikation

Protokollnummer

Titel

Phase

Psoriasis vulgaris

Bili1311.4

BI 655066 versus placebo in a multicenter randomized double-blind study in patients with moderate to severe chronic plaque psoriasis evaluating the efficacy and safety with randomized withdrawl and re-treatment

III

Psoriasis vulgaris

IM011-011

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis

II

Psoriasis vulgaris

CAIN457A2304E1

A multicenter, double-blind and open-label, 2 year extension study of subcutaneous secukinumab in prefilled syringes, assessing long-term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis treated with either a fixed dose regimen or on a retreatment at start of relapse regimen

III

Psoriasis vulgaris

PS0003

A phase 3, multicenter, randomized, double-blind, parallel-group, study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of certolizumab pegol in subjects with moderate to severe chronic plaque psoriasis

III

Psoriasis vulgaris

I1F-MC-RHAZ

A multicenter Study with a randomized, double-blind, placebo-controlled Induction dosing period followed by a randomized maintenance dosing Period and a long-term extension period to evaluate the efficacy and safety of LY2439821 in patients with moderate-to-severe palque psoriasis

III

Psoriasis vulgaris

CNTO1959PSO3008

Multicenter, randomized, open-label, efficacy assessor-blinded, active comparator-controlled phase 3b study to compare the efficacy of guselkumab to fumaric acid esters (Fumaderm® initial/ Fumaderm®) for adult patients with moderate to severe plaque psoriasis who are candidates for and naive to systemic treatment (POLARIS)

IIIb

Psoriasis vulgaris

Cain457A3401

An open-label, prospective, non-randomized, multicenter study to evaluate clear skin effect on health-related quality of life outcomes at 16 and 52 weeks in patients with moderate to severe plaque psoriasis treated with secukinumab 300mg s.c. with or without previous exposure to systemic therapy

IV

Psoriasis vulgaris

I1F-MC-RHBC

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate-to-Severe Plaque Psoriasis with a Long-Term Extension Period

III

Psoriasis vulgaris bei Kindern

CC-10004 PPSO-001

A Phase 2, multicenter, open-label, study to assess the safety, tolerability and pharmakokinetics of apremilast (CC-10004) in pediatric subjects with moderate to severe plaque psoriasis

II

Psoriasis vulgaris bei Kindern

CAIN457A2310

A randomized, double-blind, placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and etanercept (in a single-blinded arm) after twelve weeks of treatment, and to assess the safety, tolerability, and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis

III

Chronisch spontane Urtikaria

QGE031C2201

A multicenter, randomized, double-blind, placebo and active-controlled phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with hronic spontaneous urticaria (CSU)

IIb

Chronisch spontane Urtikaria

CQGE031C2201E1

An open label, multicenter, extention study to evaluate the Long-term safety of QGE031 240mg s.c. given every 4 weeks for 53 weeks in Cronic Spontaneous Urticaria patients who completed study CQGE031C2201

IIb

Hereditäre Angioödeme

Dyax DX-2930-03

A multicenter, randomized, double-blind, placebo-controlled efficacy and safety study to evaluate DX-2930 for laong-term prophylaxis against acute attacks of hereditary angioedema (HAE)

III

Hereditäre Angioödeme

Dyax DX-2930-04

HELP Study Extension: An open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE)

III

Atopische Dermatitis

R668-AD-1225

A phase 3 confirmatory study investigating the efficacy and safty of Dupilumab monotherapy administered to adult patients with moderate to severe atopic Dermatitis

III

Onychomykose

PM1331

A multicenter, randomized, double-blind, parallel, vehicle-controlles study to evaluate the efficacy and safety of P-3058 10% nail solution in the treatment of Onychomycosis

III

Pemphigus vulgaris

Pemphix WA29330

A randomized, double-blind, double-dummy, active-comparator, multicenter study to evaluate the efficacy and safety of rituximab versus MMF in patients with pemphigus vulgaris

III

Akne vulgaris

RD.06.SPR.18251

A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris

III

Archiv

Hier finden Sie eine Auflistung vergangener Studien des CRC

Kontakt

Clinical Research Center (CRC)
Gebäude 401
Station 1A, 1. OG links

Tel: +49-6131-17-5732
Fax: +49-6131-17-5594

Öffnungszeiten:
Mo. – Fr. 08:00-17:00 Uhr

Teilnahme

Um an einer unserer Studien teilzunehmen, nutzen Sie bitte folgendes Formular:

An CRC-Studie teilnehmen